Vaccines against hepatitis C virus: Harnessing Immunity to Eliminate Global Hepatitis C [Hosted by NIAID]

Vaccines against hepatitis C virus: Harnessing Immunity to Eliminate Global Hepatitis C [Hosted by NIAID]

March 24 2022
Two days
Webinar series
NIH Research Advancing Hepatitis Elimination
Video URL

The webinar series, "Moving from Hepatitis Discovery to Elimination: NIH Research Advancing Hepatitis Elimination" will kick off in 2022 with a deep-dive symposium on the latest research related to HCV vaccine development, hosted by the National Institute of Allergy and Infectious Diseases (NIAID). Over two days- March 24th and 25th- eight speakers will discuss results from clinical trials for past candidate vaccines, new findings in HCV immunology and implications for vaccine development, and emerging vaccine platforms, such as mRNA, that could be applied to HCV. Nobel Laureate, Dr. Michael Houghton, will close the symposium with his thoughts on the opportunity of HCV vaccine development within the next decade.

Plenary I. Thursday, March 24th, 2022, 12-2:30 pm ET                      

  • Welcome | John Ward, Coalition for Global Hepatitis Elimination
  • Moderators:  Rajen Koshy, (NIAID, NIH) and Jake Liang, (NIDDK, NIH)
  • The possibility and urgency of a hepatitis C vaccine |  David Thomas, Johns Hopkins University
  • Factors that limited vaccine efficacy in the first prophylactic HCV vaccine trial |  Andrea Cox, Johns Hopkins University
  • Protective immunity to HCV during natural reinfection and the development of vaccine modalities |  Arash Grakoui, Emory University
  • Structure-guided comparison of secreted vs membrane- bound forms of HCV E1E2 vaccine candidates and delivery considerations | Thomas Fuerst, University of Maryland

Plenary II. Friday, March 25th, 2022, 12-2:30 pm ET

  • Moderators: Chris Walker, Nationwide Children’s and Georg Lauer, Harvard University
  • Next Generation HCV Vaccine Antigens: What we know about HCV neutralizing antibody responses and how to leverage recent knowledge in vaccine design | Mansun Law, The Scripps Research Institute
  • HCV vaccines and neutralizing antibodies: lessons from human infection |  Justin Bailey, Johns Hopkins University
  • Systems biological assessment of immune responses to the Pfizer BioNTech BNT162b2 mRNA vaccine: lessons for HCV |  Bali Pulendran, Stanford University
  • Feasibility of delivering a HCV vaccine by the end of this decade |  Michael Houghton, University of Alberta
  • Panel Discussion:
    • Moderator: Steven Foung, Stanford University
    • Chris Walker,  Nationwide Children’s
    • Marian Major, FDA
    • David Thomas, John Hopkins University
    • Michael Houghton, University of Alberta